Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs

Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs

Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program

Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program

Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study

Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study

Antimicrobial resistance with Recce Pharmaceuticals

Antimicrobial resistance with Recce Pharmaceuticals

Engineering the future of antibiotics

Engineering the future of antibiotics

Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives

Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives

Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial

Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial

Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial

Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial

Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum

Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum

Recce Pharma welcomes approval for faster RECCE327 infusion rate

Recce Pharma welcomes approval for faster RECCE327 infusion rate